WASHINGTON — Takeda Pharmaceuticals has left the biotechnology industry’s main lobbying group, the fourth departure of a major member since December, the company confirmed.
“Takeda decided not to renew its membership with the Biotechnology Innovation Organization at the end of March 2024, aligned with the end of Takeda’s Fiscal Year,” a company spokesperson said.
Pfizer, UCB, and WuXi AppTech also recently ended their membership with the trade group, though the circumstances of WuXi’s departure were unusual. In response to BIO’s opposition to a bill that would make it difficult for WuXi to do business in the United States, the chair of the House Select Committee on the Chinese Communist Party asked the Justice Department to investigate whether BIO was lobbying for the Chinese Communist Party. BIO CEO John Crowley asked WuXi to quit the organization soon thereafter.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect